| Revision as of 11:27, 26 February 2005 editPrometheusOne (talk | contribs)Extended confirmed users528 editsmNo edit summary← Previous edit | Revision as of 11:35, 26 February 2005 edit undoPrometheusOne (talk | contribs)Extended confirmed users528 editsmNo edit summaryNext edit → | ||
| Line 5: | Line 5: | ||
| Prior to his work as a ], de Grey was formally trained in ] and ]. He argues that the fundamental knowledge necessary to develop effective anti-aging medicine mostly exists today. To that end he works to identify and promote specific technological approaches to the reversal of various aspects of aging and for the more proactive and urgent approaches to extending the healthy human lifespan. | Prior to his work as a ], de Grey was formally trained in ] and ]. He argues that the fundamental knowledge necessary to develop effective anti-aging medicine mostly exists today. To that end he works to identify and promote specific technological approaches to the reversal of various aspects of aging and for the more proactive and urgent approaches to extending the healthy human lifespan. | ||
| ], De Grey's current work at Cambridge centered around a detailed plan called ] (]) which is aimed at preventing age-related physical and cognitive decline. He is also the co-founder and chief scientist of the ], a contest designed to accelerate research into effective life extension interventions by awarding prizes to researchers who extend the lifespan of mice to unprecedented lengths. De Grey believes that once this objective has been achieved, the resulting public attention to this issue will result in more funding being applied to this kind of research, which |
], De Grey's current work at Cambridge centered around a detailed plan called ] (]) which is aimed at preventing age-related physical and cognitive decline. He is also the co-founder and chief scientist of the ], a contest designed to accelerate research into effective life extension interventions by awarding prizes to researchers who extend the lifespan of mice to unprecedented lengths. De Grey believes that once this objective has been achieved, the resulting public attention to this issue will result in more funding being applied to this kind of research, which in turn should see further progress. | ||
| ==External links== | ==External links== | ||
Revision as of 11:35, 26 February 2005
Aubrey de Grey (b. 1963) is a biogerontologist at the University of Cambridge in England who is currently working to expedite the development of a cure for human aging, a medical goal he refers to as engineered negligible senescence (senescence means aging). De Grey is also an outspoken supporter of radical life extension.
Prior to his work as a biologist, de Grey was formally trained in computer science and bioinformatics. He argues that the fundamental knowledge necessary to develop effective anti-aging medicine mostly exists today. To that end he works to identify and promote specific technological approaches to the reversal of various aspects of aging and for the more proactive and urgent approaches to extending the healthy human lifespan.
As of 2005, De Grey's current work at Cambridge centered around a detailed plan called Strategies for Engineered Negligible Senescence (SENS) which is aimed at preventing age-related physical and cognitive decline. He is also the co-founder and chief scientist of the Methuselah Mouse Prize, a contest designed to accelerate research into effective life extension interventions by awarding prizes to researchers who extend the lifespan of mice to unprecedented lengths. De Grey believes that once this objective has been achieved, the resulting public attention to this issue will result in more funding being applied to this kind of research, which in turn should see further progress.
External links
- SENS (Strategies for Engineered Negligible Senescence)
- Methuselah Mouse Prize
- Interview with BBC website, outlining views
- Popular Science article
- Technology Review article
Currently, Aubrey de Grey is seeking to attract more investors from government and private sectors, the matter remains, who will have the foresight to anticipate the new and rising markets for life extension therapies anti-aging medicine given the increasing burden placed by the aging populations of the Developed World such as USA, Japan and Western Europe. Aubrey inteview: A Cure for Aging http://www.speculist.com/archives/000056.html Aubrey Q & A on Aging http://www.speculist.com/archives/000065.html Aubrey explains the causes and prevention of aging processes -7 page article http://www.technologyreview.com/articles/05/02/issue/feature_aging.asp Articles in PDF on aging by the author http://www.gen.cam.ac.uk/sens/AdGpubs.htm
Category: